|

Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)

RECRUITINGSponsored by Yaşar Bayındır, MD
Actively Recruiting
SponsorYaşar Bayındır, MD
Started2026-03-15
Est. completion2026-12-15
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted

Summary

Chronic hepatitis B is a long-term viral infection that affects millions of people worldwide. Patients usually require lifelong antiviral treatment to control the virus and prevent liver damage. Some older antiviral medications, such as lamivudine, can lead to the development of viral resistance. This means the virus changes in a way that makes certain treatments less effective. Even though newer drugs like entecavir are stronger and more resistant to these changes, previous exposure to lamivudine may increase the risk of developing additional resistance mutations. By analyzing viral genetic material from blood samples using advanced sequencing technology, this research will help improve understanding of antiviral resistance patterns in patients with chronic hepatitis B in Turkey and may support better treatment decisions in the future.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age ≥18 years
* HBsAg positive
* Group 1: Either treatment-naïve participants with HBV DNA\>2000 IU/ml
* Group 2: Prior lamivudine therapy ≥6 months with switch to ADVor TDF or TAF
* Ability to provide informed consent

Exclusion Criteria:

* Prior entecavir exposure
* Prior telbivudine exposure
* Age \<18 years
* Inability to provide informed consent Note: Previous adefovir or (pegylated) interferon use is not an exclusion criterion.

Patients with insufficient sample volume or inadequate DNA quality for sequencing will be excluded from final analysis.

Conditions2

Hepatitis B, ChronicLiver Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.